Why Stability Data Is Non-Negotiable
Every regulatory filing for a drug substance or drug product, from the earliest IND or IMPD through to a marketing authorisation application, requires stability data. That data answers one fundamental question: for how long can the product be stored under defined conditions and remain within specification? The answer determines the retest period for the drug substance, the shelf life of the drug product, and the conditions under which both must be stored and shipped.
Building a stability programme that generates the right data, at the right time, to support each regulatory filing is a practical challenge that requires both scientific rigour and careful project planning. Getting it wrong means either filing with insufficient data and receiving a regulatory query, or generating redundant data that consumes resources without adding information.
The ICH Q1 Framework
The ICH Q1A(R2) guideline on stability testing of new drug substances and products is the primary regulatory framework for pharmaceutical stability programmes. It defines the storage conditions for long-term, intermediate, and accelerated stability studies based on the intended climatic zone of the market, the required study duration, and the minimum number of batches that must be included in a registration stability package.
| Study Type | Condition | Intended Duration | Primary Purpose |
| Long-term (Zone I/II) | 25 degrees C / 60% RH | 12 months minimum for registration; typically to proposed shelf life | Primary basis for shelf life assignment |
| Long-term (Zone IVb) | 30 degrees C / 65% RH or 40 degrees C / 75% RH | 12 months minimum for registration | Required for markets in climatic Zone IVb (e.g. India, parts of Africa) |
| Intermediate | 30 degrees C / 65% RH | 6 months minimum | Required when significant change observed at accelerated condition |
| Accelerated | 40 degrees C / 75% RH | 6 months minimum | Supports shelf life prediction; early stability screening |
| Refrigerated products | 5 degrees C +/- 3 degrees C (long-term) | 12 months minimum | For products stored at 2-8 degrees C |
| Frozen products | Minus 20 degrees C (long-term) | Programme defined by product type | For frozen drug substances and biologics |
Real-Time vs. Accelerated Stability: What Each Can and Cannot Tell You
Real-Time Stability
Real-time stability studies store samples under the intended long-term storage conditions and test them at defined intervals to assess whether the product remains within its specification over time. Real-time data is the definitive basis for shelf life assignment: a product can only be assigned a shelf life supported by real-time data collected at or beyond the proposed expiry date.
The limitation of real-time data is obvious: it takes time. A product intended to have a two-year shelf life requires two years of real-time data before that claim can be fully supported. For early clinical filings, extrapolation from available real-time data combined with accelerated data is typically accepted, but the real-time data must eventually be generated.
Accelerated Stability Studies
Accelerated stability studies store samples at elevated temperature and humidity conditions, typically 40 degrees Celsius at 75% relative humidity, to accelerate the rate of chemical and physical degradation. The results allow scientists to predict long-term stability behaviour based on the degradation kinetics observed under stress conditions, using the Arrhenius relationship between temperature and reaction rate.
Accelerated data is valuable for comparing formulation options quickly, for generating supportive data for early clinical filings, and for predicting the degradation pathways that will need to be monitored in the long-term programme. However, accelerated data cannot substitute for real-time data in a registration-stage shelf life claim, and for some degradation mechanisms, particularly physical instability in amorphous formulations or moisture-driven hydrolysis, the Arrhenius relationship does not hold.
Stress Testing: Beyond ICH Stability
ICH Q1A(R2) stability studies are designed to generate the data needed for regulatory filings. Stress testing, as described in the related ICH Q1B guideline on photostability and in general scientific practice, goes further: it exposes the product to extreme conditions, including high temperature, oxidation, acid and base hydrolysis, and intense light, to force degradation and identify the degradation products that will appear in real-time stability samples.
Stress testing is typically conducted on the drug substance before formulation work begins, and again on the drug product once the formulation is established. The degradation products identified in stress studies inform the choice of stability-indicating analytical methods, the excipient compatibility assessment, and the packaging selection. A formulation that fails rapidly under oxidative stress conditions is not suitable for storage in a packaging system that allows oxygen ingress.
Stability Testing Across Ardena’s Network
Ardena operates GMP stability storage facilities across its network of sites, including temperature-controlled chambers and freezers covering the ICH long-term, intermediate, and accelerated conditions for ambient, refrigerated, and frozen products. Stability samples are managed under a formal stability protocol with a documented pull schedule, and analytical testing is conducted by the relevant site’s analytical team using validated stability-indicating methods.
For programmes that require stability storage across multiple product types or at multiple sites, Ardena’s project management structure ensures that the stability programme is tracked centrally and that any out-of-trend or out-of-specification stability results are escalated promptly.
